Ista Istalol Intent: Outsample, Outpromote Other Ophthalmic Beta Blockers
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Ista plans to outsample competing products in an effort to make Istalol the leading agent in the $170 mil. ophthalmic beta blocker market.